Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stem Cell Therapeutics has revealed its plans for the near to mid-term which include the commencement of two phase II human clinical trials to evaluate the company's lead therapy, NTx-265, as a treatment for stroke.
Subscribe to our email newsletter
After identifying NTx-265 as its lead compound, completing dosing in a phase I study, and raising $8.5 million in an initial public offering, Stem Cell Therapeutics (SCT) has revealed its ongoing plans for the development of the drug.
These plans include animal studies validating the proposed clinical regimen for NTx-265, a phase IIa safety study for the compound to be initiated in the first quarter of 2006, and a phase IIb proof of concept study with anticipated completion in 2008.
The company’s therapeutic approach has shown efficacy in animal models of central nervous system disorders, including stroke.
“Each year there are approximately 15 million people worldwide that suffer a stroke, many of whom require an effective treatment to promote functional recovery following that stroke. SCT continues to focus its efforts toward developing drugs that will address this major unmet medical need,” Dr Joseph Tucker, SCT’s president and chief executive officer.